Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-10-14
Tempus AI, Inc.
Provides molecular diagnostics, clinical workflow software, and governed healthcare data and AI tools to providers and life sciences customers.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

More than a lab, not yet software
The upside case is a mix shift: keep diagnostics growing, then prove that governed data, MRD, and clinical workflow execution deserve a better multiple than a normal lab. The path is credible, but it still runs through approvals, reimbursement, and M&A integration.

Analysis

Thesis
Tempus can outgrow a normal diagnostics company because every added test, workflow deployment, and biopharma program expands a governed clinical data asset that can be monetized again through software, monitoring, and regulated care execution; if MRD, xF reimbursement, and data/apps mix keep improving, the business can rerate meaningfully by 2031.
Last Economy Alignment
Tempus owns governed clinical data, lab output, and regulated workflow surfaces that become more valuable as AI improves. Its capture is not mainly seat-based, so the bigger risk is reimbursement, regulation, or trust failure rather than generic AI price compression.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.2x (from 5 most recent analyses)
Reasoning
I do not need a heroic share gain or a pure-software multiple for the case to work. Tempus can create solid equity value if it keeps core diagnostics growing, internalizes more MRD economics, proves biopharma data contracts are durable, and adds workflow revenue that is harder for generic AI to commoditize. The upside is mostly a quality-of-revenue shift from lab-heavy to regulated data, monitoring, and execution rails, but approval and reimbursement gates keep the ceiling below the best oncology-platform winners.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The upside path is real but sequential: Tempus must sustain core diagnostics growth, close and integrate Personalis, expand MRD sales coverage, win xF approval plus ADLT reimbursement, and convert data and software bookings into durable revenue while avoiding dilution or a trust incident. Missing one of those gates likely hurts the rerating more than it hurts near-term revenue.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.69
They control hard-to-get clinical data, lab results, and the regulated workflow where those outputs get used, so better AI makes their rails more valuable. The risk is that reimbursement, approvals, or a trust failure slows the mix shift before higher-quality revenue becomes dominant.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$70.06
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case